
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1646264/publications.pdf Version: 2024-02-01



Δηειμείη \λ/Δσμάερ

#	Article	IF	CITATIONS
1	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 2015, 17, 1064-1075.	1.2	485
2	Current concepts and management of glioblastoma. Annals of Neurology, 2011, 70, 9-21.	5.3	380
3	Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. Journal of Neurosurgery, 2015, 122, 803-811.	1.6	376
4	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
5	Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathologica, 2013, 126, 365-384.	7.7	264
6	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nature Medicine, 2018, 24, 1611-1624.	30.7	229
7	Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology, 2017, 19, 1460-1468.	1.2	213
8	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathologica, 2012, 123, 223-233.	7.7	204
9	5â€Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer, 2010, 116, 1545-1552.	4.1	199
10	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathologica, 2014, 128, 279-289.	7.7	191
11	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathologica, 2013, 125, 891-900.	7.7	177
12	The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. Journal of Neuro-Oncology, 2009, 95, 401-411.	2.9	157
13	5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement. PLoS ONE, 2013, 8, e76988.	2.5	138
14	Incidence of atypical teratoid/rhabdoid tumors in children. Cancer, 2010, 116, 5725-5732.	4.1	126
15	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018, 20, 873-884.	1.2	119
16	Atypical teratoid rhabdoid tumor: improved longâ€ŧerm survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992–2012. Cancer Medicine, 2014, 3, 91-100.	2.8	99
17	Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the <i>IDH1-R132H</i> Mutation in Diffuse Glioma Biopsy Specimens. Journal of Neuropathology and Experimental Neurology, 2011, 70, 715-723.	1.7	98
18	Glioma Survival Prediction with Combined Analysis of In Vivo ¹¹ C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. Journal of Nuclear Medicine, 2018, 59, 892-899.	5.0	94

#	Article	IF	CITATIONS
19	Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. Neurosurgical Review, 2012, 35, 381-391.	2.4	86
20	Glioblastoma survival. Current Opinion in Neurology, 2014, 27, 666-674.	3.6	82
21	IgG4- related disease: an orphan disease with many faces. Orphanet Journal of Rare Diseases, 2014, 9, 110.	2.7	81
22	<scp><i>BRAF</i></scp> â€Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <scp>CD</scp> 34 Expression. Brain Pathology, 2014, 24, 221-229.	4.1	72
23	Analysis of the surgical benefits of 5-ALA–induced fluorescence in intracranial meningiomas: experience in 204 meningiomas. Journal of Neurosurgery, 2016, 125, 1408-1419.	1.6	69
24	Novel Histopathological Patterns in Cortical Tubers of Epilepsy Surgery Patients with Tuberous Sclerosis Complex. PLoS ONE, 2016, 11, e0157396.	2.5	69
25	Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biology and Therapy, 2008, 7, 1377-1385.	3.4	67
26	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clinical and Experimental Metastasis, 2013, 30, 357-368.	3.3	66
27	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer, 2014, 83, 83-89.	2.0	63
28	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. Cancer Investigation, 2012, 30, 615-621.	1.3	60
29	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer, 2013, 80, 278-283.	2.0	59
30	Trabectedin has promising antineoplastic activity in highâ€grade meningioma. Cancer, 2012, 118, 5038-5049.	4.1	57
31	Analysis of 5-aminolevulinic acid–induced fluorescence in 55 different spinal tumors. Neurosurgical Focus, 2014, 36, E11.	2.3	55
32	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathologica, 2014, 128, 879-891.	7.7	54
33	The MOBI-Kids Study Protocol: Challenges in Assessing Childhood and Adolescent Exposure to Electromagnetic Fields from Wireless Telecommunication Technologies and Possible Association with Brain Tumor Risk. Frontiers in Public Health, 2014, 2, 124.	2.7	53
34	Spectroscopic imaging with spectral domain visible light optical coherence microscopy in Alzheimer's disease brain samples. Biomedical Optics Express, 2017, 8, 4007.	2.9	51
35	O ⁶ â€methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas. Cancer, 2009, 115, 1070-1080.	4.1	48
36	Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical Review, 2013, 36, 45-56.	2.4	48

#	Article	IF	CITATIONS
37	5-ALA–induced fluorescence as a marker for diagnostic tissue in stereotactic biopsies of intracranial lymphomas: experience in 41 patients. Neurosurgical Focus, 2018, 44, E7.	2.3	46
38	Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. , 2014, 33, 6-14.		45
39	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology, 2012, 60, 885-894.	2.9	44
40	Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology, 2010, 42, 547-552.	0.6	42
41	Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. , 2015, 34, 250-257.		42
42	Visualization of neuritic plaques in Alzheimer's disease by polarization-sensitive optical coherence microscopy. Scientific Reports, 2017, 7, 43477.	3.3	41
43	Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. Magnetic Resonance Imaging, 2012, 30, 139-147.	1.8	39
44	Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas. Neurosurgical Focus, 2015, 38, E4.	2.3	39
45	Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 512-520.	1.9	38
46	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. PLoS ONE, 2013, 8, e55464.	2.5	38
47	Molecular diagnostics: techniques and recommendations for 1p/19q assessment. CNS Oncology, 2015, 4, 295-306.	3.0	37
48	Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables. Acta Neuropathologica Communications, 2018, 6, 135.	5.2	37
49	High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI. NeuroImage: Clinical, 2020, 28, 102433.	2.7	37
50	Overview of cerebrospinal fluid cytology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 563-571.	1.8	36
51	Systematic histopathological analysis of different 5-aminolevulinic acid–induced fluorescence levels in newly diagnosed glioblastomas. Journal of Neurosurgery, 2018, 129, 341-353.	1.6	35
52	Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. Journal of Neurosurgery, 2009, 111, 563-571.	1.6	34
53	Trends in incidence, survival and mortality of childhood and adolescent cancer in Austria, 1994â¿2011. Cancer Epidemiology, 2016, 42, 72-81.	1.9	33
54	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 632-641.	1.2	33

#	Article	IF	CITATIONS
55	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro-Oncology, 2013, 15, 112-121.	1.2	31
56	Is Intraoperative Pathology Needed if 5-Aminolevulinic-Acid-Induced Tissue Fluorescence Is Found in Stereotactic Brain Tumor Biopsy?. Neurosurgery, 2020, 86, 366-373.	1.1	29
57	Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. Acta Neuropathologica, 2011, 122, 787-790.	7.7	27
58	Gamma Knife Radiosurgery in Recurrent Glioblastoma. Stereotactic and Functional Neurosurgery, 2016, 94, 265-272.	1.5	27
59	Ape1 guides DNA repair pathway choice that is associated with drug tolerance in glioblastoma. Scientific Reports, 2017, 7, 9674.	3.3	27
60	Joint embedding: A scalable alignment to compare individuals in a connectivity space. NeuroImage, 2020, 222, 117232.	4.2	27
61	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. European Radiology, 2017, 27, 1556-1567.	4.5	26
62	5-ALA in Suspected Low-Grade Gliomas: Current Role, Limitations, and New Approaches. Frontiers in Oncology, 2021, 11, 699301.	2.8	26
63	Amplification and overexpression of <i><scp>CMET</scp></i> is a common event in brain metastases of nonâ€small cell lung cancer. Histopathology, 2014, 65, 684-692.	2.9	25
64	Beyond backscattering: optical neuroimaging by BRAD. Biomedical Optics Express, 2018, 9, 2476.	2.9	25
65	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. Journal of Neuro-Oncology, 2020, 148, 187-198.	2.9	25
66	Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. , 2013, 32, 148-158.		25
67	MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. Pituitary, 2017, 20, 643-653.	2.9	24
68	Macroscopic fluorescence-lifetime imaging of NADH and protoporphyrin IX improves the detection and grading of 5-aminolevulinic acid-stained brain tumors. Scientific Reports, 2020, 10, 20492.	3.3	24
69	Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naĀ ⁻ ve gliomas. Neuro-Oncology, 2018, 20, 411-419.	1.2	22
70	LAG-3 expression in the inflammatory microenvironment of glioma. Journal of Neuro-Oncology, 2021, 152, 533-539.	2.9	22
71	Retinal analysis of a mouse model of Alzheimer's disease with multicontrast optical coherence tomography. Neurophotonics, 2020, 7, 1.	3.3	22
72	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. SpringerPlus, 2014, 3, 111.	1.2	21

#	Article	IF	CITATIONS
73	Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma. Cancers, 2021, 13, 566.	3.7	21
74	Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas. , 2014, 33, 108-111.		21
75	Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. Journal of Neuro-Oncology, 2012, 109, 323-330.	2.9	20
76	Clinical presentation of young people (10–24Âyears old) with brain tumors: results from the international MOBI-Kids study. Journal of Neuro-Oncology, 2020, 147, 427-440.	2.9	20
77	Assessment of pathological features in Alzheimer's disease brain tissue with a large field-of-view visible-light optical coherence microscope. Neurophotonics, 2018, 5, 1.	3.3	20
78	Blood Alterations Preceding Clinical Manifestation of Glioblastoma. Cancer Investigation, 2012, 30, 625-629.	1.3	19
79	Distributed changes of the functional connectome in patients with glioblastoma. Scientific Reports, 2020, 10, 18312.	3.3	19
80	Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. Npj Vaccines, 2020, 5, 5.	6.0	19
81	Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. Journal of Neurosurgery, 2020, 133, 1032-1043.	1.6	19
82	Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance. Cancers, 2020, 12, 1707.	3.7	18
83	Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry. , 2013, 32, 269-285.		18
84	Elevated blood markers 1 year before manifestation of malignant glioma. Neuro-Oncology, 2010, 12, 1004-1008.	1.2	16
85	Revealing brain pathologies with multimodal visible light optical coherence microscopy and fluorescence imaging. Journal of Biomedical Optics, 2019, 24, 1.	2.6	16
86	Frequent overexpression of ErbB – receptor family members in brain metastases of nonâ€small cell lung cancer patients. Apmis, 2013, 121, 1144-1152.	2.0	15
87	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. Journal of Neuro-Oncology, 2013, 112, 347-354.	2.9	14
88	Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study. BMC Cancer, 2021, 21, 754.	2.6	14
89	MRI features of Binswanger's disease predict prognosis and associated pathology. Annals of Clinical and Translational Neurology, 2014, 1, 813-821.	3.7	13
90	Ex-vivo analysis of quantitative 5-ALA fluorescence intensity in diffusely infiltrating gliomas using a handheld spectroscopic probe: Correlation with histopathology, proliferation and microvascular density. Photodiagnosis and Photodynamic Therapy, 2019, 27, 354-361.	2.6	13

#	Article	IF	CITATIONS
91	Improved Diagnostic Imaging of Brain Tumors by Multimodal Microscopy and Deep Learning. Cancers, 2020, 12, 1806.	3.7	13
92	Thalidomide as Palliative Treatment in Patients with Advanced Secondary Glioblastoma. Oncology, 2015, 88, 173-179.	1.9	12
93	Evaluating cellularity and structural connectivity on whole brain slides using a custom-made digital pathology pipeline. Journal of Neuroscience Methods, 2019, 311, 215-221.	2.5	12
94	Prognostic Value of 5-ALA Fluorescence, Tumor Cell Infiltration and Angiogenesis in the Peritumoral Brain Tissue of Brain Metastases. Cancers, 2021, 13, 603.	3.7	12
95	Fluorescence Lifetime Imaging and Spectroscopic Co-Validation for Protoporphyrin IX-Guided Tumor Visualization in Neurosurgery. Frontiers in Oncology, 2021, 11, 741303.	2.8	12
96	Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. Radiotherapy and Oncology, 2019, 130, 139-148.	0.6	11
97	PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival. Journal of Personalized Medicine, 2021, 11, 624.	2.5	11
98	The Digital Brain Tumour Atlas, an open histopathology resource. Scientific Data, 2022, 9, 55.	5.3	11
99	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. Anti-Cancer Drugs, 2014, 25, 723-728.	1.4	10
100	Haematopoietic stem cell transplantation for treatment of primary <scp>CNS</scp> lymphoma: singleâ€centre experience and literature review. European Journal of Haematology, 2015, 95, 75-82.	2.2	10
101	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Cancer Immunology, Immunotherapy, 2021, 70, 3643-3650.	4.2	10
102	Innervated ectopic salivary gland associated with RathkeÂ's cleft cyst clinically mimicking pituitary adenoma. , 2013, 32, 171-175.		9
103	Novel crystalloid oligodendrogliopathy in hereditary spastic paraplegia. Acta Neuropathologica, 2012, 124, 583-591.	7.7	8
104	Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. Acta Oncológica, 2019, 58, 967-976.	1.8	8
105	Mitochondrial disorder mimicking rheumatoid disease. Zeitschrift Fur Rheumatologie, 2019, 78, 875-880.	1.0	8
106	Improved accuracy of quantitative birefringence imaging by polarization sensitive <scp>OCT</scp> with simple noise correction and its application to neuroimaging. Journal of Biophotonics, 2021, 14, e202000323.	2.3	8
107	Intrameningioma Metastasis: A Wolf in Sheep's Clothing? Experience from a Series of 7 Cases. World Neurosurgery, 2019, 132, 169-172.	1.3	7
108	Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease. Journal of Oncology Pharmacy Practice, 2013, 19, 170-174.	0.9	6

#	Article	IF	CITATIONS
109	Clinical Neuropathology image 1-2015: Crystal-storing histiocytosis of the central nervous system. , 2015, 34, 4-5.		6
110	Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS). , 2017, 36, 5-14.		6
111	MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals. Pituitary, 2018, 21, 266-273.	2.9	6
112	Efficacy, Outcome, and Safety of Elderly Patients with Glioblastoma in the 5-ALA Era: Single Center Experience of More Than 10 Years. Cancers, 2021, 13, 6119.	3.7	6
113	Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling. Clinical Neuroradiology, 2020, 30, 599-605.	1.9	5
114	How to predict the consistency and vascularity of meningiomas by MRI: an institutional experience. Neurological Research, 2021, 43, 693-699.	1.3	5
115	Polarization-sensitive imaging with simultaneous bright- and dark-field optical coherence tomography. Optics Letters, 2019, 44, 4040.	3.3	5
116	Secondary gliosarcoma with massive invasion of meninges, skull base, and soft tissue, and systemic metastasis. , 2013, 32, 522-524.		5
117	Enhanced expression of autophagyâ€related p62 without increased deposits of neurodegenerationâ€associated proteins in glioblastoma and surrounding tissue – An autopsyâ€based study. Brain Pathology, 2022, 32, e13058.	4.1	5
118	Comparison of Intensity- and Polarization-based Contrast in Amyloid-beta Plaques as Observed by Optical Coherence Tomography. Applied Sciences (Switzerland), 2019, 9, 2100.	2.5	4
119	Results of Phosphorus Magnetic Resonance Spectroscopy for Brain Metastases Correlate with Histopathologic Results. World Neurosurgery, 2019, 127, e172-e178.	1.3	4
120	PD1 and PD-L1 expression in glioblastoma Journal of Clinical Oncology, 2014, 32, 2011-2011.	1.6	4
121	Sex-Specific Differences in Primary CNS Lymphoma. Cancers, 2020, 12, 1593.	3.7	3
122	Clinical neuropathology practice guide 1-2013: Molecular subtyping of glioblastoma: ready for clinical use?. , 2013, 32, 5-8.		3
123	Evolving evidence on tumor and germline genetic classification of gliomas: implications for etiology and survival studies. , 2016, 35, 31-37.		3
124	7T HR FID-MRSI Compared to Amino Acid PET: Glutamine and Glycine as Promising Biomarkers in Brain Tumors. Cancers, 2022, 14, 2163.	3.7	3
125	Disseminated Intravascular Coagulation in Secondary Glioblastoma due to Excessive Intraoperative Bleeding: Case Report and Review of the Literature. World Neurosurgery, 2016, 90, 702.e7-702.e11.	1.3	2
126	Visible light spectral domain optical coherence microscopy system for ex vivo imaging. Proceedings of SPIE, 2017, , .	0.8	2

#	Article	IF	CITATIONS
127	Polarization-sensitive optical coherence microscopy of human brain samples. , 2017, , .		2
128	SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma. Cancers, 2022, 14, 1984.	3.7	2
129	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases Journal of Clinical Oncology, 2014, 32, 2012-2012.	1.6	1
130	Visible light spectral domain optical coherence microscopy system for ex vivo brain imaging. , 2017, , .		1
131	Simultaneous Bright and Dark Field Optical Coherence Tomography Using Few-Mode Fiber Detection for Neuropathology Imaging. , 2018, , .		1
132	Ex-vivo Alzheimer's disease brain tissue investigation: a multiscale approach using 1060-nm swept source optical coherence tomography for a direct correlation to histology. Neurophotonics, 2020, 7, 035004.	3.3	1
133	Improved Protoporphyrin IX-Guided Neurosurgical Tumor Detection with Frequency-Domain Fluorescence Lifetime Imaging. Applied Sciences (Switzerland), 2022, 12, 1002.	2.5	1
134	Letter to the Editor Complex-I defect with minimal manifestations. Archives of Medical Science, 2014, 1, 200-202.	0.9	0
135	Presumed mitochondrial disease manifesting with recurrent syncopes. Journal of Cardiovascular Medicine, 2014, 15, 167-169.	1.5	0
136	NTCT-09IGF-1 IS NOT ELEVATED IN PATIENTS WITH HGG TREATED WITH RADIOCHEMOTHERAPY. Neuro-Oncology, 2015, 17, v174.1-v174.	1.2	0
137	COMP-12. TOWARDS BIG DATA IN DIGITAL NEUROPATHOLOGY WITH THE DIGITAL BRAIN TUMOR ATLAS. Neuro-Oncology, 2018, 20, vi66-vi66.	1.2	0
138	ACTR-32. 5-ALA FLUORESCENCE IS A POWERFUL MARKER FOR DETECTION OF UNEXPECTED GLIOBLASTOMA TISSUE DURING SURGERY OF RADIOLOGICALLY SUSPECTED LOW-GRADE GLIOMAS. Neuro-Oncology, 2018, 20, vi18-vi18.	1.2	0
139	DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM. Neuro-Oncology, 2018, 20, vi76-vi76.	1.2	0
140	SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES. Neuro-Oncology Advances, 2019, 1, i33-i33.	0.7	0
141	RARE-49. SEX-SPECIFIC SURVIVAL ANALYSIS IDENTIFIES DIFFERENTIAL CLUSTERS OF PROGNOSTIC RELEVANCE IN PATIENTS WITH PRIMARY CNS LYMPHOMA. Neuro-Oncology, 2019, 21, vi232-vi232.	1.2	0
142	TMIC-09. MULTIMODAL VISIBLE LIGHT OPTICAL COHERENCE MICROSCOPY AND FLUORESCENCE IMAGING OF GLIOBLASTOMA REGIONAL SAMPLES. Neuro-Oncology, 2019, 21, vi248-vi249.	1.2	0
143	BIMG-04. MAPPING HETEROGENEITY OF HIGH-GRADE GLIOMA METABOLISM USING HIGH RESOLUTION 7T MRSI. Neuro-Oncology Advances, 2021, 3, i1-i1.	0.7	0
144	Correlation of large brain edema with favorable prognosis in patients with single brain metastases Journal of Clinical Oncology, 2012, 30, 2053-2053.	1.6	0

#	Article	IF	CITATIONS
145	Investigating Pathological Features of Alzheimer's Disease in Human and Mouse Brain Tissue with Visible Light Optical Coherence Microscopy. , 2018, , .		0
146	Imaging Brain Pathology in Alzheimer's Disease by Contrast-Enhanced Optical Coherence Tomography. , 2018, , .		0
147	Spatiotemporal evolution of a low-grade glioma with divergent oligodendroglial and astrocytic lineages. , 2018, 37, 82-84.		0
148	Combined visible light optical coherence microscopy and fluorescence imaging setup to investigate 5-aminolevulinic acid postive glioma samples. , 2019, , .		0
149	Multicentric malignant glioma with striking morphologic heterogeneity and early and extensive metastatic spread to the bone. , 2019, 38, 261-268.		0
150	NIMG-20. MULTI-HABITAT RADIOMICS UNRAVELS DISTINCT PHENOTYPIC SUBTYPES OF GLIOBLASTOMA WITH CLINICAL AND GENOMIC SIGNIFICANCE. Neuro-Oncology, 2020, 22, ii151-ii151.	1.2	0